Dana-Farber’s Breast Oncology Center shared a post on X about a paper by M.J. Naughton et al. published in ESMO Open:
“New in ESMO Open. Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early Breast Cancer.”
Title: Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
Authors: M.J. Naughton, D.M. Zahrieh, M. Gnant, N. Zdenkowski, J. Lemieux, J.J. Mao, V. Bjelic-Radisic, E. Shinn, M. Balic, C. Thomssen, J.L. Meisel, G.M. Ruiz, S. Loibl, C. Isaacs, D. Cameron, F.M. Henao-Carrasco, M.P. Goetz, C.F. Singer, G. Werutsky, H.S. Rugo, M. Vetter, L.-M. Tseng, K. Miller, F. Fitzal, J.M. Gil Gil, H. Park, B. Linderholm, E. Bajetta, Z. Dayao, A. Prat, K. Ehrhardt, O. Metzger, A. Arahmani, E.H. Law, A.H. Partridge, L.A. Carey, A. Zoroufy, A.C. Dueck, P. O’Brien, D. Hlauschek, A. DeMichele, E.L. Mayer
You can read the Full Article in ESMO Open.
More posts featuring Dana-Farber’s Breast Oncology Center.
